Valneva’s share capital is composed of:
- 90 923 298 ordinary shares (ISIN FR0004056851), with a nominal value of €0.15;
- 17 836 719 Preferred shares (ISIN FR0011472943), with a nominal value of €0.01;
- 20 514 preferred shares (unlisted and non-transferable) convertible into ordinary shares, with a nominal value of €0.15.
Each Preferred share having a nominal value of €0.01 will be converted into 0.5246 (rounded to 0.5250) new Valneva ordinary shares, if and when the Condition defined in article 13.3 of the Articles of Incorporation has been met.
- Auditors’ report(s) on the observance by the Company Valneva SE of the particular rights associated with the Preferred Shares
Each Convertible preferred share having a nominal value of €0.15 will be converted into new Valneva ordinary shares if the conditions of such conversion defined in article 13.4 of the Articles of Incorporation are met.
Note: As stated in the press release published on June 2, 2016 and in accordance with the Company’s Articles of Association (Article 13.3, paragraph 3(i)), Valneva SE’s preferred shares (ISIN FR0011472943) which were issued in the 2013 merger with Intercell AG, are expected to be redeemed at their nominal value of €0.01 per preferred share in June 2020, as the Company no longer expects approval of the Pseudomonas vaccine within their seven-year term (which would have led to conversion into Valneva SE ordinary shares at the end of this term).